论文部分内容阅读
作者采用双盲法对41例蛛网膜下腔出血(SAH)病人随机给予尼莫地平(21例)或安慰剂(20例)以研究其血小板功能。全部病人于发病后≤96小时入院。入院前二周内和入院后未用过非类固醇抗炎药,尿液检查无水杨酸盐。40例经CT确诊,1例经腰穿和手术证实,38例曾手术。两组性别比例、平均年龄、临床分级、临床和CT表现均相似。开始尼莫地平剂量为0.25μg/kg/min,连续静滴,二小时后剂量增至0.5μg/kg/min,维持给药直到SAH后7～10天。如果在发病≥8天手术则至少维持给药至术后3天,以后改为口服(60mg Q4h)到SAH后21天。对每个病人于SAH后1～5天(早期)、7～10天(中期)、11～18天(晚期)分别进行血小板聚集力测定、血小板计数和血栓素B_2(TXB_2)的浓度测定。结果显示(1)尼莫地平对血小板聚集力无显著
The authors used a double-blind method in 41 patients with subarachnoid hemorrhage (SAH) were randomized to nimodipine (21 patients) or placebo (20 patients) to study its platelet function. All patients were hospitalized ≤96 hours after onset. Non-steroidal anti-inflammatory drugs were not used within two weeks before admission and after admission, and no salicylate was detected in urine. 40 cases were diagnosed by CT, 1 case was confirmed by lumbar puncture and surgery, 38 cases had surgery. The two groups of sex ratio, average age, clinical grade, clinical and CT were similar. Nimodipine was started at a dose of 0.25 μg / kg / min for continuous intravenous infusion and after 2 hours the dose was increased to 0.5 μg / kg / min and maintenance was continued until 7-10 days after SAH. If the onset of ≥ 8 days surgery is maintained at least until 3 days after the operation, later changed to oral (60mg Q4h) to SAH after 21 days. Platelet aggregation, platelet count and concentration of TXB_2 were determined in each patient after SAH 1 ~ 5 days (early), 7 ~ 10 days (middle), 11 ~ 18 days (late) The results showed that (1) nimodipine had no significant effect on platelet aggregation